The results of the present study revealed that the ORR for first-line EGFR-TKI treatment was higher in EGFR-mutant NSCLC patients with low plasma sPD-L1 levels than in those with high sPD-L1 levels. Here, EGFR is linked to non-small cell lung carcinoma.